PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.
PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
|PharmGKB Accession Id:||PA305|
|Cytogenetic Location:||chr12 : p13.31 - p13.31|
|GP mRNA Boundary†:||chr12 : 6456009 - 6486896|
|GP Gene Boundary†:||chr12 : 6453009 - 6496896|
UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.View on UCSC Browser
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
Diuretics Pathway, Pharmacodynamics
Diagrammatic representation of candidate genes involved in the pharmacodynamics of thiazide diuretics, loop diuretics and potassium-sparing diuretics in a stylized kidney cell.
Glucocorticoid Pathway - Transcription Regulation, Pharmacodynamics
Model displaying genes which may be involved in the nuclear complex formed that regulates transcription in response to glucocorticoids.
Publications related to SCNN1A: 5
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]
||WNK kinases and the kidney. Experimental cell research. 2012. Hoorn Ewout J, et al.|
||Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. Journal of hypertension. 2010. Irvin Marguerite R, et al.|
||The genetics of loop diuretic effects. The pharmacogenomics journal. 2010. Vormfelde S V, et al.|
||Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clinical pharmacology and therapeutics. 2007. Vormfelde S V, et al.|
||The gene expression of the amiloride-sensitive epithelial sodium channel alpha-subunit is regulated by antagonistic effects between glucocorticoid hormone and ras pathways in salivary epithelial cells. The Journal of biological chemistry. 1999. Lin H H, et al.|